|
|
Volumn 13, Issue 3, 2012, Pages 233-234
|
|
NICE guidance on cetuximab, bevacizumab, and panitumumab for treatment of metastatic colorectal cancer after first-line chemotherapy.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
BEVACIZUMAB;
CETUXIMAB;
MONOCLONAL ANTIBODY;
PANITUMUMAB;
COLORECTAL TUMOR;
COST BENEFIT ANALYSIS;
DRUG COST;
ECONOMICS;
EVIDENCE BASED MEDICINE;
HUMAN;
METASTASIS;
NATIONAL HEALTH SERVICE;
NOTE;
PRACTICE GUIDELINE;
TREATMENT OUTCOME;
UNITED KINGDOM;
ANTIBODIES, MONOCLONAL;
ANTIBODIES, MONOCLONAL, HUMANIZED;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
COLORECTAL NEOPLASMS;
COST-BENEFIT ANALYSIS;
DRUG COSTS;
EVIDENCE-BASED MEDICINE;
GREAT BRITAIN;
HUMANS;
PRACTICE GUIDELINES AS TOPIC;
STATE MEDICINE;
TREATMENT OUTCOME;
MLCS;
MLOWN;
|
|
EID: 84859415747
PISSN: None
EISSN: 14745488
Source Type: Journal
DOI: 10.1016/s1470-2045(12)70044-x Document Type: Note |
|
Times cited : (17)
|
|
References (0)
|
